Modalis Therapeutics Licensed Exegenesis Bio Technology
The companies have partnered to improve delivery of a Duchenne muscular dystrophy treatment.
Updated on Sept. 21, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies prioritize patient health over their own profits?
Modalis Therapeutics has licensed muscle-targeting AAV delivery technology from Exegenesis Bio. The collaboration aims to improve the delivery of the CRISPR-GNDM-based therapy MDL-201 for patients with Duchenne muscular dystrophy.
Why it matters
The deal allows for the integration of specialized capsids to enhance the effectiveness of epigenome-editing therapies. By targeting skeletal muscle while reducing liver exposure, the partnership seeks to address the underlying protein deficiencies associated with muscular dystrophy.
The agreement grants rights to the EMC181 engineered AAV capsid, which is designed to increase tissue-specific targeting. This technology will be paired with the MDL-201 payload, which utilizes CRISPR-GNDM epigenome-editing to boost utrophin expression.
The players
Exegenesis Bio
Exegenesis Bio is a biotechnology company based in Horsham, Pennsylvania, that specializes in gene delivery platforms.
Modalis Therapeutics
Modalis Therapeutics is a biotechnology firm headquartered in Tokyo that develops CRISPR-based epigenome-editing therapies.
The details
Exegenesis Bio will supply its proprietary muscle-targeting platform, while Modalis Therapeutics contributes its expertise in epigenome-editing. Together, they are working to overcome current challenges in gene-therapy delivery to skeletal and cardiac tissues.
Timeline
The licensing agreement was announced on September 21, 2026.
The Tech Race
This partnership reflects a broader industry shift toward solving delivery bottlenecks in next-generation gene therapies. The use of engineered AAV capsids represents a move away from legacy viral vectors that often lacked the specificity required for effective muscular dystrophy treatment.
For patients and families, this collaboration represents a potential long-term step toward more efficient and less toxic gene therapies. It signals progress toward refining treatments that aim to address muscular dystrophy at its genetic source.
The takeaway
This licensing deal highlights the importance of combining specialized delivery vehicles with advanced gene-editing payloads to improve therapeutic outcomes. Future advancements in this space will likely focus on maximizing protein expression levels while minimizing off-target effects in the liver.
Further reading
Learn more about the latest developments in the sector on our Biotech page.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you trust that pharmaceutical companies prioritize patient health over their own profits?
